
CLAIMS

1. Use of a compound of Formula (II):



(II),

or a pharmaceutically acceptable salt thereof, wherein

each R^9 is independently -H, -hydrocarbyl, -aryl, -aralkyl, -heteroaryl, -heterocyclyl, -C(O)O(alkyl), -OC(O)(alkyl), $-C(O)NH_2$, -C(O)NH(alkyl), -C(O)N(alkyl)(alkyl), -NHC(O)(alkyl), N(alkyl)C(O)(alkyl),or $-SO_2NH_2$;

each R^{10} is independently -H, -OH, $-NH_2$, -NH(alkyl), -N(alkyl)(alkyl), hydrocarbyl, -O-alkyl, -O-alkenyl, aryl, -O-aryl, aralkyl, -O-aralkyl, heteroaryl, -O-heteroaryl, heterocyclyl, -O-heterocyclyl, halo, $-OCF_3$, -C(O)O(alkyl), -OC(O)(alkyl), $-C(O)NH_2$, -C(O)NH(alkyl), -C(O)N(alkyl)(alkyl), $-NHC(O)(C_2-C_{10}$-alkyl), -N(alkyl)C(O)(alkyl), -OC(O)O(alkyl), $-OC(O)NH_2$, -OC(O)NH(alkyl), -OC(O)N(alkyl)(alkyl), -CHNH, -CHN(alkyl), or $-SO_2NH_2$;



each of Q^1, Q^2, and Q^3 is independently CR^{10} or N;



X is CHR^{10}, S, O, or NR^9; and



each m is independently an integer from 0-3


in the manufacture of a medicament for treating or preventing a hepatic steatosis.



2. The use of claim 1, wherein the compound has the structure:



IIa:  ; IIb:  ;



IIc:  ; IId  ;



IIe:  ; IIf:  ;


IIg:  ;



IIi:  ; IIj:  ;


IIk:  ; IIl:  ;



IIm:  ; IIn:  ;



IIo:  ; IIp:  ;


IIr:  ;



IIs:  ; IIt:  ;



IIv:  ;

IIw:  ; IIx:  ;

IIy:  ; IIz:  ;

IIaa  ;

IIgg:  ; IIhh:  ;


IIii:  ; or IIjj:  ,

or a pharmaceutically acceptable salt of any of the foregoing.

3. The use of claim 1, wherein R^9 is H and R^{10} is OH.

4. The use of claim 3, wherein each m is 1.

5. The use of claim 1, wherein the compound has the structure:

IIa: 

.

6. The use of claim 1, wherein the hepatic steatosis is alcoholic hepatic steatosis or non-alcoholic hepatic steatosis.



7. The use of claim 1, wherein the compound or pharmaceutically acceptable salt therof is present in a composition that further comprises a pharmaceutically acceptable vehicle or carrier.



8. The use of claim 7, wherein the composition is formulated for oral administration.



9. The use of claim 7, wherein the composition is in the form of a tablet or capsule.



10. The use of claim 7, wherein the compound or pharmaceutically acceptable salt thereof is present in the composition in an amount of about 1 mg to about 1,000 mg.

11. Use of a compound having the structure:

IIh:  ; IIq:  ;

IIu:  ; IIbb  ;

IIcc:  ; IIdd:  ;

IIee:  ; or IIff: 

or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for treating or preventing a hepatic steatosis.

12. The use of claim 11, wherein the hepatic steatosis is alcoholic hepatic steatosis or non-alcoholic hepatic steatosis.

13. The use of claim 11, wherein the compound or pharmaceutically acceptable salt thereof is a present in a composition that further comprises a pharmaceutically acceptable vehicle or carrier.

14. The use of claim 13, wherein the composition is formulated for oral administration.

15. The use of claim 13, wherein the composition is in the form of a tablet or capsule.

16. The use of claim 13, wherein the compound or pharmaceutically acceptable salt thereof is present in the composition in an amount of about 1 mg to about 1,000 mg.